-
AUPH Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Aurinia Pharmaceuticals (AUPH)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 83.43 mm | 83.43 mm | 83.43 mm | 83.43 mm | 83.43 mm | 83.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 556.33 k | 135.67 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 1.15 mm | 279.67 k | n/a | n/a |
Cash remaining | n/a | n/a | 82.29 mm | 83.15 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 147.9 | 612.9 | n/a | n/a |
13F holders | Current |
---|---|
Total holders | 197 |
Opened positions | 37 |
Closed positions | 22 |
Increased positions | 62 |
Reduced positions | 48 |
13F shares | Current |
---|---|
Total value | 506.11 bn |
Total shares | 64.07 mm |
Total puts | 1.51 mm |
Total calls | 948.70 k |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 8.95 mm | $80.39 bn |
Tang Capital Management | 8.43 mm | $75.70 bn |
Armistice Capital | 6.40 mm | $57.47 bn |
ILJIN SNT | 6.40 mm | $0.00 |
NEA Management | 3.97 mm | $35.65 bn |
STT State Street | 2.92 mm | $26.20 bn |
Geode Capital Management | 1.76 mm | $15.84 bn |
GS The Goldman Sachs Group, Inc. | 1.75 mm | $15.73 bn |
Vanguard | 1.73 mm | $15.53 bn |
MS Morgan Stanley | 1.65 mm | $14.77 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Dec 24 | Tang Kevin C | Common Shares | Buy | Acquire P | Yes | No | 9.09 | 500,000 | 4.55 mm | 8,429,500 |
6 Dec 24 | Tang Kevin C | Common Shares | Buy | Acquire P | Yes | No | 9.01 | 400,000 | 3.60 mm | 7,929,500 |
5 Dec 24 | Tang Kevin C | Common Shares | Buy | Acquire P | Yes | No | 8.91 | 300,000 | 2.67 mm | 7,529,500 |
21 Nov 24 | David R.W. Jayne | Common Shares | Grant | Acquire A | No | No | 0 | 12,135 | 0.00 | 56,499 |
21 Nov 24 | David R.W. Jayne | Director Stock Option Common Shares | Grant | Acquire A | No | No | 8.24 | 18,641 | 153.60 k | 18,641 |
21 Nov 24 | Johnson Craig A | Common Shares | Grant | Acquire A | No | No | 0 | 20,631 | 0.00 | 20,631 |
21 Nov 24 | Johnson Craig A | Director Stock Option Common Shares | Grant | Acquire A | No | No | 8.24 | 31,688 | 261.11 k | 31,688 |
21 Nov 24 | Smith Karen L. | Common Shares | Grant | Acquire A | No | No | 0 | 12,135 | 0.00 | 24,807 |
21 Nov 24 | Smith Karen L. | Director Stock Option Common Shares | Grant | Acquire A | No | No | 8.24 | 18,641 | 153.60 k | 18,641 |
21 Nov 24 | Jill Leversage | Common Shares | Grant | Acquire A | No | No | 0 | 12,135 | 0.00 | 25,053 |